Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Nonrandomized, Open Label Study to Examine the Effect of Hepatic Impairment on the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.'

NCT00437606 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00437606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00437606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Nonrandomized, Open Label Study to Examine the Effect of Hepatic Impairment on the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.'
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2007
Completion date
June 30, 2007
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2